(5R,6S)-2-{[(2S,5R)-2-{[(3R)-4-acetyl-3-methylpiperazin-1-yl]carbonyl}-5-methylpyrrolidin-1-yl]carbonyl}-5,6-bis(4-chlorophenyl)-3-isopropyl-6-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole | 1033710-38-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (5R,6S)-2-{[(2S,5R)-2-{[(3R)-4-acetyl-3-methylpiperazin-1-yl]carbonyl}-5-methylpyrrolidin-1-yl]carbonyl}-5,6-bis(4-chlorophenyl)-3-isopropyl-6-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole
• 英文别名: 1-[(2R)-4-[(2S,5R)-1-[(5R,6S)-5,6-bis(4-chlorophenyl)-6-methyl-3-propan-2-yl-5H-imidazo[2,1-b][1,3]thiazole-2-carbonyl]-5-methylpyrrolidine-2-carbonyl]-2-methylpiperazin-1-yl]ethanone
• CAS: 1033710-38-1
• 化学式: C₃₅H₄₁Cl₂N₅O₃S
• 分子量: 682.714
• InChiKey: IFRGRPZUIVLSHG-LNRYSTOCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  46
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.49
• 拓扑面积：
  102
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-benzyl 2-tert-butyl (2S)-5-methoxypyrrolidine-1,2-dicarboxylate 在 copper(I) bromide dimethylsulfide complex 、 palladium 10% on activated carbon 、 氢气 、 1-羟基苯并三唑 、 苯甲醚 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， -78.0~40.0 ℃ 、101.33 kPa 条件下， 反应 51.5h， 生成 (5R,6S)-2-{[(2S,5R)-2-{[(3R)-4-acetyl-3-methylpiperazin-1-yl]carbonyl}-5-methylpyrrolidin-1-yl]carbonyl}-5,6-bis(4-chlorophenyl)-3-isopropyl-6-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole
  参考文献：
  名称：

  Synthesis and evaluation of novel orally active p53–MDM2 interaction inhibitors

  摘要：

  We have discovered and reported potent p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold. Our lead showed strong activity in vitro, but did not exhibit antitumor efficacy in vivo for the low metabolic stability. In order to obtain orally active compounds, we executed further optimization of our lead by the improvement of physicochemical properties. Thus we furnished optimal compounds by introducing an alkyl group onto the pyrrolidine at the C-2 substituent to prevent the metabolism; and modifying the terminal substituent of the proline motif improved solubility. These optimal compounds exhibited good PK profiles and significant antitumor efficacy with oral administration on a xenograft model using MV4-11 cells having wild type p53. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.04.056

文献信息

• Imidazothiazole derivatives
  申请人：Kawato Haruko

  公开号：US20090312310A1

  公开（公告）日：2009-12-17

  There is provided a novel compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. The present invention provides an imidazothiazole derivative represented by the following formula (1) having various substituents that inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity: wherein R 1 , R 2 , R 3 , R 4 , and R 5 in the formula (1) each has the same meaning as defined in the specification.

  提供了一种新的化合物，它抑制小鼠双分子分钟2（Mdm2）蛋白与p53蛋白之间的相互作用，并展现出抗肿瘤活性。本发明提供了一种咪唑噻唑衍生物，其表示为以下公式（1），具有各种取代基，可抑制Mdm2蛋白与p53蛋白之间的相互作用并展现出抗肿瘤活性：其中，公式（1）中的R1、R2、R3、R4和R5每个都具有规范中定义的相同含义。
• IMIDAZOTHIAZOLE DERIVATIVES
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2103619A1

  公开（公告）日：2009-09-23

  There is provided a novel compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. The present invention provides an imidazothiazole derivative represented by the following formula (1) having various substituents that inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity: wherein R1, R2, R3, R4, and R5 in the formula (1) each has the same meaning as defined in the specification.

  本发明提供了一种新型化合物，它能抑制小鼠双分 2（Mdm2）蛋白和 p53 蛋白之间的相互作用，并具有抗肿瘤活性。本发明提供了一种由下式（1）代表的咪唑噻唑衍生物，该衍生物具有各种取代基，可抑制 Mdm2 蛋白和 p53 蛋白之间的相互作用，并具有抗肿瘤活性： 其中，式（1）中的 R1、R2、R3、R4 和 R5 各具有与说明书中定义的相同含义。
• Synthesis and evaluation of novel orally active p53–MDM2 interaction inhibitors
  作者：Masaki Miyazaki、Hiroyuki Naito、Yuuichi Sugimoto、Keisuke Yoshida、Haruko Kawato、Tooru Okayama、Hironari Shimizu、Masaya Miyazaki、Mayumi Kitagawa、Takahiko Seki、Setsuko Fukutake、Yoshinobu Shiose、Masashi Aonuma、Tsunehiko Soga

  DOI：10.1016/j.bmc.2013.04.056

  日期：2013.7

  We have discovered and reported potent p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold. Our lead showed strong activity in vitro, but did not exhibit antitumor efficacy in vivo for the low metabolic stability. In order to obtain orally active compounds, we executed further optimization of our lead by the improvement of physicochemical properties. Thus we furnished optimal compounds by introducing an alkyl group onto the pyrrolidine at the C-2 substituent to prevent the metabolism; and modifying the terminal substituent of the proline motif improved solubility. These optimal compounds exhibited good PK profiles and significant antitumor efficacy with oral administration on a xenograft model using MV4-11 cells having wild type p53. (C) 2013 Elsevier Ltd. All rights reserved.